These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 18725050)

  • 1. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations.
    Khachman D; Conil JM; Georges B; Saivin S; Houin G; Toutain PL; Laffont CM
    J Antimicrob Chemother; 2011 Aug; 66(8):1798-809. PubMed ID: 21653603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of enrofloxacin in turkeys.
    Dimitrova DJ; Lashev LD; Yanev SG; Pandova B
    Res Vet Sci; 2007 Jun; 82(3):392-7. PubMed ID: 17107697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection.
    Zelenitsky SA; Ariano RE
    J Antimicrob Chemother; 2010 Aug; 65(8):1725-32. PubMed ID: 20558470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches.
    Conil JM; Georges B; de Lussy A; Khachman D; Seguin T; Ruiz S; Cougot P; Fourcade O; Houin G; Saivin S
    Int J Antimicrob Agents; 2008 Dec; 32(6):505-10. PubMed ID: 18768301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
    Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
    Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
    Fish DN
    Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective.
    Pea F; Poz D; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2006 Aug; 58(2):380-6. PubMed ID: 16735422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE; Golden JA; McIver M; Zurlinden E
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?
    Lipman J; Gous AG; Mathivha LR; Tshukutsoane S; Scribante J; Hon H; Pinder M; Riera-Fanego JF; Verhoef L; Stass H
    Intensive Care Med; 2002 Apr; 28(4):493-500. PubMed ID: 11967606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
    Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
    J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
    Burgess DS; Hall RG
    Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.
    Conte JE; Golden JA; Kelly MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Jun; 25(6):523-9. PubMed ID: 15885987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
    Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
    Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.